Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
Savara, Inc. (SVRA)
Last savara, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
savarapharma.com/investors/events-presentations
Company Research
Source: Business Wire
-- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 ---- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI Delivered Via PARI’s Proprietary eFlow® Nebulizer System -- LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its intention to grant a patent application covering the liquid formulation of MOLBREEVI, an orally inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF).“The liquid formulation and drug-device patents will provide protection in Europe through March 2041 and March 2043, respectively, and strengthen the Company’s intellectual property portfolio for MOLBREEVI, our potentially first-in-class therapy to treat autoimmune PAP,” said Matt Pauls, J.D., M.B.A, Chair and Chief Executive Offic
Show less
Read more
Impact Snapshot
Event Time:
SVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SVRA alerts
High impacting Savara, Inc. news events
Weekly update
A roundup of the hottest topics
SVRA
News
- Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* [Yahoo! Finance]Yahoo! Finance
- Savara Inc. ticks higher amid takeover speculation [Seeking Alpha]Seeking Alpha
- Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer SystemBusiness Wire
- Savara Announces Participation in Upcoming Investor Healthcare ConferencesBusiness Wire
- Savara: A High-Risk Opportunity [Seeking Alpha]Seeking Alpha
SVRA
Earnings
- 11/12/25 - Miss
SVRA
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- SVRA's page on the SEC website